Clinical Trials Using Gefitinib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Gefitinib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC
The main purpose of this study is to evaluate the safety and efficacy of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in participants with stage IV non small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Del19 and L858R). Safety and tolerability of ramucirumab in combination with erlotinib will be assessed in the first portion (Part A) before proceeding to the second portion of this study (Part B). The purpose of Part C is to determine the efficacy and safety of ramucirumab in combination with gefitinib in previously untreated East Asian participants with EGFR mutation-positive metastatic NSCLC and of ramucirumab in combination with osimertinib in those participants whose disease progressed on ramucirumab and gefitinib and that have T790M - positive metastatic NSCLC.
Location: 3 locations
Osimertinib and Gefitinib in Treating Patients with EGFR Mutant Stage IV Non-small Cell Lung cancer
This randomized phase I trial studies the side effects and best dose of osimertinib when given together with gefitinib in treating patients with EGFR mutant stage IV non-small cell lung cancer. Osimertinib and gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 2 locations
EGFR Inhibitor EGF816 and Gefitinib in Treating Patients with Recurrent or Stage IIIB-IV EGFR-Mutant Non-small Cell Lung Cancer
This phase II trial studies how well EGFR inhibitor EGF816 and gefitinib work in treating patients with EGFR-mutant non-small cell lung cancer that has come back or is stage IIIB-IV. EGFR inhibitor EGF816 and gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: Massachusetts General Hospital, Charlestown, Massachusetts
Gefitinib in Treating Patients With Newly Diagnosed Liver Cancer That Can Be Removed By Surgery
This pilot clinical trial studies gefitinib in treating patients with newly diagnosed liver cancer that can be removed by surgery. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland